Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
SA Funt, JE Rosenberg - Nature reviews Clinical oncology, 2017 - nature.com
Many patients diagnosed with muscle-invasive bladder cancer (MIBC) will develop distant
metastatic disease. Over the past three decades, perioperative cisplatin-based …
metastatic disease. Over the past three decades, perioperative cisplatin-based …
[HTML][HTML] Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for …
P Grivas, E Kopyltsov, PJ Su, FX Parnis, SH Park… - European Urology, 2023 - Elsevier
Abstract Background In JAVELIN Bladder 100, avelumab first-line maintenance plus best
supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) versus …
supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) versus …
Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients
ARAH Hamid, FR Ridwan, D Parikesit, F Widia… - BMC urology, 2020 - Springer
Background Most patients with muscle-invasive bladder cancer (MIBC) developed
metastasis within 2 years, even after radical cystectomy (RC). The recurrence rate of MIBC …
metastasis within 2 years, even after radical cystectomy (RC). The recurrence rate of MIBC …
Bacillus Calmette–Guérin in Immuno-Regulation of Alzheimer's Disease
BY Klein, CL Greenblatt, ON Gofrit… - Frontiers in Aging …, 2022 - frontiersin.org
Bacillus Calmette–Guérin is frequently the treatment of choice of superficial bladder cancer.
Exposing the urinary bladder of elderly patients with bladder cancer to the BCG vaccine …
Exposing the urinary bladder of elderly patients with bladder cancer to the BCG vaccine …
Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States
MD Galsky, SK Pal, SW Lin, S Ogale… - Bladder …, 2018 - content.iospress.com
Background: Outcomes for patients with metastatic bladder cancer (mBC) are generally poor
and progressively worse following first-line (1L) chemotherapy. Objective: To evaluate …
and progressively worse following first-line (1L) chemotherapy. Objective: To evaluate …
[HTML][HTML] Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer (KEYNOTE-052): outcomes in older patients by age and performance …
P Grivas, ER Plimack, AV Balar, D Castellano… - European urology …, 2020 - Elsevier
Background Patients with treatment-naive advanced urothelial cancer (UC) ineligible for
cisplatin-based chemotherapy are typically older and have comorbidities, representing a …
cisplatin-based chemotherapy are typically older and have comorbidities, representing a …
Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy–a feasibility study
GA Taarnhøj, H Lindberg, LH Dohn, LH Omland… - Health and Quality of …, 2020 - Springer
Background Electronic collection of patient-reported outcomes (ePROs) is becoming
widespread in health care, but the implementation into routine cancer care during therapy …
widespread in health care, but the implementation into routine cancer care during therapy …
Development and validation of nomograms predicting the 5-and 8-year overall and cancer-specific survival of bladder cancer patients based on SEER program
P Wen, J Wen, X Huang, F Wang - Journal of Clinical Medicine, 2023 - mdpi.com
Background: Bladder cancer is often prone to recurrence and metastasis. We sought to
construct nomogram models to predict the overall survival (OS) and cancer-specific survival …
construct nomogram models to predict the overall survival (OS) and cancer-specific survival …
Patient reported symptoms associated with quality of life during chemo‐or immunotherapy for bladder cancer patients with advanced disease
GA Taarnhøj, C Johansen, H Lindberg… - Cancer …, 2020 - Wiley Online Library
Background Bladder cancer (BC) patients with advanced disease have poor outcomes. The
use of patient‐reported outcomes (PROs) could lead to improvements in symptom …
use of patient‐reported outcomes (PROs) could lead to improvements in symptom …
Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma
Y Freifeld, R Ghandour, N Singla, S Woldu… - … Oncology: Seminars and …, 2019 - Elsevier
Purpose To identify preoperative risk factors for disease recurrence, following radical
nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), and to create a …
nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), and to create a …